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ABSTRACT
TREATING VERY LARGE NON-SMALL CELL LUNG CANCERS: A SURVIVAL
ANALYSIS USING NATIONAL CANCER DATABASES.
Amy C. Moreno, Daniel Morgensztern, Daniel J. Boffa, Roy H. Decker, James B. Yu,
Frank C. Detterbeck, Zuoheng Wang, Michal G. Rose, and Anthony W. Kim.
Department of Thoracic Surgery, Yale University School of Medicine, New Haven, CT.

Very large primary non-small cell lung cancers (NSCLC), defined as those >7 cm,
remain a therapeutic challenge due to known survival disadvantage compared to smaller
tumors and lack of specific studies in this population. This study compares the effect of
various treatment modalities on survival of patients with large NSCLC with none or
positive hilar lymph node involvement (T3>7cmN0 and T3>7cmN1, respectively).
The Surveillance, Epidemiology, and End Results (SEER) database was used to
identify patients undergoing a lobectomy or pneumonectomy for T3>7cmN0 NSCLC from
1999 to 2008. Patients were categorized into groups based on type of surgery performed
and whether neoadjuvant radiation therapy (NRT) was used. The National Cancer Data
Base (NCDB) was used to identify adult patients who were diagnosed with T3>7cmN1
NSCLC

from

1999-2005.

Nonsurgical

treatments

included

chemoradiation,

chemotherapy, radiation therapy, or no treatment whereas primary surgical treatments
included surgery only, chemoradiation or chemotherapy prior to surgery (CxR-S or C-S,
respectively), chemoradiation or chemotherapy after surgery (S-CxR or S-C,
respectively), or postoperative radiation therapy (S-PORT). Five-year overall (OS) and

lung cancer specific survival (LCSS) were estimated by the Kaplan-Meier method and
comparisons made using log-rank tests and Cox regression models.
A total of 1,301 surgical patients with T3>7cmN0 NSCLC were evaluated using the
SEER database, including 1,232 undergoing primary surgical therapy (PST) and 69
receiving NRT. NRT was not associated with improvements in 5-year OS (48% vs. 41%,
P=.06) or LCSS (59% vs. 52%, P=.12) compared to PST. Lobectomies were associated
with better 5-year OS (43% vs. 33%; P=.006) and LCSS (54% vs. 43%, P=.005)
compared to pneumonectomies. On multivariate analysis, NRT did not produce any
significant advantage in OS (P=.24) and LCSS (P=.21). Using the NCDB, a total of 642
patients with T3>7cmN1 NSCLC were evaluated: 425 nonsurgical and 217 primary
surgical treatments. Primary surgical treatments were associated with an improved 5-year
OS of 28% compared to 8% and 4% for primary nonsurgical treatments and no
treatments, respectively (P<.001). Specific nonsurgical treatment 5-year OS were 11%,
5%, 2%, 4% for chemoradiation, chemotherapy, radiation therapy, and no treatment,
respectively (P<.001). Primary surgical treatment 5-year OS were 16%, 44%, 40%, 40%,
38%, and 18% for surgery only, CxR-S, C-S, S-CxR, S-C, and S-PORT, respectively
(P<.001). On multivariate analysis, surgery and chemotherapy in most combinations
were associated with significantly improved OS compared to chemoradiation only (C-S
hazard ratio (HR), 0.4 [95% confidence interval, 0.18-0.88], P=.02; CxR-S HR, 0.41
[0.19-0.9], P=.03; S-C HR, 0.4 [0.19-0.85], P=.02).
Our results demonstrate that neoadjuvant radiation therapy, which most likely was
a combination of chemotherapy and radiation, was not associated with improvements in
OS or LCSS compared to primary surgical therapy for patients with T3>7cmN0 NSCLC.

When feasible, lobectomy appears more beneficial than pneumonectomy in terms of
long-term survival. For patients with T3>7cmN1 NSCLC, surgery with systemic therapy
delivered in a neoadjuvant or adjuvant fashion is associated with improvements in longterm overall survival. Finally, when surgical resection is not feasible, definitive
chemoradiation therapy should be considered as an equal alternative to surgical resection
alone.
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1
INTRODUCTION
With approximately 288,190 newly diagnosed cases estimated in 2013, lung
cancer is a dangerously prevalent disease in the United States. It is the second most
common cancer in both men and women, accounting for roughly 14% of all new cancers.
As the most common cause of cancer deaths, lung cancer takes the lives of almost onethird of all cancer patients annually, a toll that surpasses colon, breast, and prostate
cancer deaths combined1. While the chances of a man or woman to develop lung cancer
in his or her lifetime nowadays is about 1 in 13 or 1 in 16, respectively, it is interesting to
note that lung cancer was once considered a very rare disease prior to the 20th century. By
1900, only about 140 cases had been published in medical literature. Shortly thereafter,
findings of primary lung tumors in autopsied bodies began to rise dramatically. In 1912,
Isaac Adler, author of the world’s first monograph on lung cancer, was one of the first to
infer a possible association between tobacco abuse (and alcohol) with the simultaneous
“decided increase” in incidence of malignant neoplasms of the lung2. A global lung
cancer epidemic was later recognized in the 1940s and 1950s as growing evidence of the
epidemiology, cellular pathology, and chemical analytics pointed back to cigarettes as the
primary cause3. However, with the expansion of cigarette manufacturing and effective
propagandizing to the public, this evidence was argued for years while a worldwide
addictive habit quickly solidified.
Tobacco smoking is now undisputedly the leading risk factor for lung cancer.
According to the 2012 International Agency for Research on Cancer (IARC) risk
assessment, lung cancer kills about 1.59 million people per year globally with 80-95% of
cases entirely preventable4,5. Other risk factors include radon, a naturally occurring
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radioactive gas that results from the breakdown of uranium in soil and rocks, asbestos
exposure, and a history of radiation therapy to the lungs or chest for other cancers such as
Hodgkin’s lymphoma5. Lung cancer is primarily a disease of the elderly with two out of
three people diagnosed being over the age of 65. This finding has been thought to
correlate with an increased likelihood of tobacco smoke exposure with increasing age.
For unknown reasons, black men are about 20% more likely to develop lung cancer than
white men1. Major public awareness campaigns, banning of cigarette smoking in public
areas, and a steadfast mission to detect and aggressively treat lung cancer as early as
possible have all created a small appearing yet significant impact towards thwarting the
rising trend of lung cancer. Over the past decade, rates for new lung and bronchus
cancers have been falling on average 1.3% each year and mortality trends are similarly
decreasing by about 2.3% per year for men and 0.7% per year among women6,7.
When analyzing lung cancers histologically, they can be broadly divided into two
main types: small cell and non-small cell lung cancer (NSCLC). NSCLC constitutes the
majority of lung cancers and includes histologic subtypes such as adenocarcinoma, large
cell carcinoma, and squamous cell carcinoma. Roughly one-quarter of patients with
NSCLC are diagnosed at an early stage (stage I or II), and treatment typically includes
surgery with or without chemotherapy in order to achieve curative rates of 60-80% and
40-50% for stages I and II disease, respectively8-10. On the other extreme of the spectrum,
treatment goals for stage IV disease usually involve palliative measures to deal with
metastatic disease. For the remaining 35% to 45% of patients diagnosed with stage III
NSCLC, curative-intent treatment is a controversial topic. The differences in treatment
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within stage III owes to the inclusion of a heterogeneous group of lesions that constitute
this stage.
According to the 7th edition of the American Joint Committee on Cancer (AJCC)
and the International Union Against Cancer (UICC) staging system, stage III lung cancer
can be divided into two broad subcategories, stage IIIA and stage IIIB disease11. Each
stage can be further analyzed by the TNM classification method that incorporates
information regarding tumor dimensions (T), lymph node invasion (N), and whether
metastatic disease is present (M). Stage IIIA mirrors the heterogeneity of all of stage III
disease as it is also constituted by a heterogeneous mix of lesion sets [Table 1]. With
respect to tumor size and/or extension, T3 lesions encompass lesions that invade the chest
wall, are central in nature, or are associated with additional tumors in the same lobe.
Tumors that are greater than 7 cm also fall into the T3 primary tumor category.
Tumor size has long since been recognized as a valuable prognostic factor in
NSCLC. Adopted worldwide in 1974, the TNM classification is revised nearly every 10
years. Prior to the 7th edition of the AJCC staging system, the 6th edition defined only one
tumor size cut off of 3 cm to separate T1 from T2 lesions. This threshold value for tumor
size was selected after several studies demonstrated a significant difference in survival
between patients with ≤3 cm (T1) and >3 cm (T2) lesions12-15. Since then more studies
indicating survival differences at other larger tumor sizes led to the further division of T2
lesions to T2a (>3 cm but ≤5 cm) and T2b (> 5 cm but ≤7 cm) lesions and the upstaging
of tumors >7 cm to a T3 status11,16,17. These major revisions that focused mainly on the T
descriptor carry a significant impact on diagnostic staging and subsequent treatment
selection. More specifically, very large tumors >7 cm with no lymph node involvement
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were upstaged from stage IB to stage IIB (T3>7 cmN0) disease while tumors >7 cm with
positive ipsilateral hilar lymph node involvement were upstaged from stage IIB to stage
IIIA (T3>7 cmN1) disease.
Many clinicians, in particular surgeons, would agree that T3N0 tumors benefit
from surgical resection as the initial mode of therapy. Current National Comprehensive
Cancer Network (NCCN) and American College of Chest Physicians (ACCP) guidelines
recommend lung-sparing anatomic resections (lobectomy) over pneumonectomies if
anatomically appropriate and margin-negative resections can be achieved10,18. The use of
definitive, neoadjuvant, or adjuvant chemotherapy with or without radiation therapy for
this subset of patients with early stage disease is arguable due to the absence of metastatic
spread to local lymph nodes and

reasonably high curative rates with surgery alone.

However, data from the CALGB study which demonstrated that a statistically significant
survival advantage exists for patients with early stage NSCLC tumors ≥4 cm who are
treated with adjuvant paclitaxel/carboplatin would then suggest that given the large
nature of these tumors, there is a benefit of adding adjuvant therapy19. Moreover, there
may be a potential impact of neoadjuvant therapy on “downstaging” or reducing tumor
burden prior to surgical resection for patients with very large tumors that are categorized
as early stage disease. In clinical practice, the optimal strategy for this group remains
undefined.
Similarly, the optimal treatment strategy for T3>7 cmN1 NSCLC is controversial.
Part of the confusion results from a lack of studies analyzing patterns of care and
associated survival outcomes for this particular group of patients. As noted earlier, Stage
IIIA disease represents a heterogeneous set of locally advanced lung cancers that
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occasionally include surgical resection as part of a multimodality treatment
algorithm9,18,20. Most studies analyzing the role of neoadjuvant or adjuvant therapy for
the very large T3 lesion subset of T3 lesions are frequently buried among general data
analyzing neoadjuvant or adjuvant therapy for stage II or III disease21-23. With the recent
upstaging of T3>7 cmN1 NSCLC to a Stage IIIA designation it is difficult to assess the
effects of treatment on survival for this subset of patients when most studies on Stage
IIIA disease are primarily focused on treating mediastinal or N2 nodal disease. Looking
at this heavily studied population, patients with N2 nodal disease who comprise the
majority of Stage IIIA NSCLC cases are approached with a wide variation in treatment
strategies that are heavily influenced by physician interpretation of the actual extent of
the disease and the patient’s ability to withstand treatment24-26. Overall, there is a general
consensus that patients with Stage III NSCLC would benefit from a multimodality
therapeutic approach whenever feasible20,27. However, it is arguable that results from
studies evaluating the effect of various treatments for N2 nodal disease can be directly
applied to patients with T3>7 cmN1 NSCLC lesions.
In general, there are not very many studies that specifically address variations in
the treatment of T3>7 cmN0 and T3>7 cmN1 lesions. It is clear that very large tumors that
are greater than 7 cm with no or minimal hilar lymph node involvement present a unique
set of problems for clinicians. Large lesions typically will not respond completely to the
effects of definitive chemotherapy and radiation therapy. Similarly, as aforementioned,
the benefit of these very large tumors in the context of neoadjuvant therapy remains
questionable. The challenge associated with resecting these large tumors is that the extent
of the operation required to remove these lesions is substantial and often times followed
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by adjuvant therapy in clinical practice. To our knowledge, there has been no study
assessing current treatment patterns and their effect on long-term survival for patients
with very large NSCLCs with no or minimal lymph node involvement.

7
STATEMENT OF PURPOSE AND SPECIFIC HYPOTHESIS

The purpose of this study was to examine the efficacy of different treatment strategies on
long-term survival of patients with very large NSCLC tumors clinically staged as
T3>7cmN0 or T3>7 cmN1 using large national datasets. Our primary hypothesis is that there
is a practice pattern that exists which may be associated with an improved outcome for
very large tumors with none or minimal lymph node burden. Our secondary hypothesis is
that within this group, whether there is a difference or not, there are specific
characteristics associated with certain patients with very large tumors that result in more
favorable outcomes.

SPECIFIC AIMS
1. To identify current patterns of treatment for very large NSCLCs that are clinically
staged as T3>7cmN0 or T3>7cmN1
2. To determine the practice pattern associated with the best clinical outcomes
including the longest survival
3. To identify factors that are associated with improved clinical outcomes compared
to other patients with stage T3>7cmN0 or T3>7cmN1 NSCLC undergoing alternative
modalities of treatment
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METHODS
NOTE: All data analysis described below was performed by the primary author.
Data Sources
This study utilized two national cancer databases. The Surveillance,
Epidemiology, and End Results database provided clinical, demographic, and treatment
data for patients diagnosed with very large (>7 cm) NSCLC tumors with no lymph node
involvement (T3>7cmN0 disease). The National Cancer Database provided clinical,
demographic, treatment and overall survival data for patients diagnosed with very large
(>7 cm) NSCLC tumors with positive ipsilateral hilar lymph node involvement
(T3>7cmN1 disease).

The Surveillance Epidemiology End Results (SEER) Public-Use Dataset
The Surveillance, Epidemiology, and End Results (SEER) database, a national
cancer surveillance program, has collected clinicopathologic data on all incident cancer
cases since 1973 and now includes 18 regional population-based cancer registries that
cover approximately 28% of the United States population. Sponsored by the National
Cancer Institute, the database is highly representative of national demographics and
contains information on primary tumor site, tumor histology and morphology, stage at
diagnosis, first course of treatment, follow up, and cause of death28.

Patient Selection
We restricted the analysis to patients who were of age 20 years and older and
were diagnosed with NSCLC from 1999 to 2008. As the current seventh edition AJCC
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lung cancer staging definition for Stage IIB tumors is broad and complex, we selectively
specified for a clinical TNM staging diagnosis of a tumor size >7 cm with no clinical
lymph node involvement (cN0) or metastasis (cM0) in our inclusion criteria. All eligible
patients had histologically confirmed NSCLC. The histology of the tumors coded in the
SEER database according to the third edition of the International Classification of
Disease for Oncology (ICD-O-3) was used to classify tumors into the following five
categories: large cell carcinomas (ICD-O-3 codes 8012 and 8013); squamous cell
carcinomas (ICD-O-3 codes 8050-8052 and 8070-8078); adenocarcinomas (ICD-O-3
codes 8140, 8141, 8143, 8147, 8250-8255, 8260, 8310, 8430, 8480, 8481, 8490, and
8571-8575); adenosquamous carcinomas (ICD-O-3 codes 8560 and 8570); and other
NSCLC tumors (ICD-O-3 codes 8010, 8020, 8046)29. All patients with distant metastasis
or tumor sizes less than 7 cm were excluded. The SEER program Coding and Staging
Manual was consulted to select patients who received definitive surgical therapy in the
form of a lobectomy (surgical codes 30-45) or pneumonectomy (surgical codes 55-70)30.
These patients were then categorized into groups depending on type of surgery performed
and whether neoadjuvant radiation therapy (NRT) was provided prior to surgery. The
final sample size included 1,301 patients.

The National Cancer Database (NCDB)
The National Cancer Data Base (NCDB) is a joint project of the Commission on
Cancer of the American College of Surgeons and the American Cancer Society. Begun in
1989, it is a nationwide oncology outcomes database that captures detailed information of
nearly 70% of all newly diagnosed cases of cancer in the United States and currently
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contains over 29 million records from hospital cancer registries across the country31.
Therefore, the NCDB is an excellent resource to investigate patient and tumor
characteristics, radiation, chemotherapy, complications, and long-term survival. The data
used in this study are derived from a deidentified NCDB file. The American College of
Surgeons and the Commission on Cancer have not verified and are neither responsible for
the analytic or statistical methodology employed, nor the conclusions drawn from these
data by the investigator. All information regarding patient and tumor characteristics,
initial treatment, and outcomes were selected for the cohort using the “βPUF (Participant
User File) Data Dictionary Item” descriptions found at the National Cancer Database
website32.

Patient Selection
The analysis was restricted to patients who were age 20 years and older and
diagnosed with NSCLC as their only cancer diagnosis from 1999 to 2005. The
International Classification of Disease for Oncology (ICD-O-3) codes used in the NCDB
to identify the NSCLC cohort has been previously described above in the “The
Surveillance Epidemiology End Results (SEER) Public-Use Dataset” section and the
following subcohorts were created: large cell carcinomas, squamous cell carcinomas,
adenocarcinomas, adenosquamous carcinomas, and other NSCLC tumors. All patients
had a documented tumor size >7 cm but ≤20 cm, clinically positive ipsilateral lymph
node involvement (cN1) and no distant metastasis (cM0). There is a group of patients in
the NCDB with tumor sizes labeled as 7 cm which could potentially include a subset of
patients with larger tumors that were estimated downward, but for the purposes of this
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portion of the study which focused on proper T3>7cmN1 NSCLC identification they were
excluded. Patients who received surgical therapy in the form of lobectomy or
pneumonectomy with negative surgical margins were included. Similar surgical codes as
recorded in the SEER T3>7cmN0 NSCLC analysis above were used.
Treatment combination sequences were determined for each patient using NCDB
data items that described the date of treatment (either surgical, chemotherapy/systemic, or
radiation therapy) in relation to date of diagnosis. The possible treatment modalities for
the nonsurgical sub-cohort (NST) included no treatment (None); chemotherapy only (C);
radiation therapy only (RT); or chemoradiation therapy (CxR). The primary surgical
treatment (PST) combinations included the following: surgery only (S); chemotherapy
prior to surgery (C-S); chemoradiation prior to surgery (CxR-S); surgery followed by
chemotherapy (S-C); surgery followed by chemoradiation (S-CxR); or surgery and
postoperative radiation therapy (S-PORT).
Preoperative or neoadjuvant radiation therapy is often a proxy for preoperative
chemoradiation and is seldom provided without chemotherapy prior to surgery. However,
we found minimal patients with records indicating neoadjuvant radiation therapy without
chemotherapy prior to surgery. As this treatment modality represented a disproportionate
minority, it was excluded from the analysis. Any patient with distant metastasis or
records indicating therapy was for palliative measures was excluded. Patients undergoing
surgical resections with positive margins were also excluded for several reasons
including small sample size (less than 10% of the surgical population) and the likelihood
that this select group of patients received adjuvant therapy due to the positive surgical
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margins which could therefore skew the results in evaluating the impact of adjuvant
therapy after complete surgical resection. The final sample size included 642 patients.

Variables
Patient information obtained from the SEER database included gender, age,
race/ethnicity, age at diagnosis, histology and size of primary tumor, stage along with
degree lymph node involvement, type of surgery, the performance of neoadjuvant
radiation therapy (NRT), survival time, and cause of death. Patient information obtained
from the NCDB included gender, age, race/ethnicity, age at diagnosis, histology and size
of primary tumor, stage along with degree lymph node involvement, type of surgery, the
addition or absence of neoadjuvant and adjuvant therapy, and survival time in months.
For both databases, patients who had a lobectomy include a simple lobectomy,
sleeve lobectomy, bilobectomy, and extended lobectomy while those with a
pneumonectomy consist of both a simple and extended pneumonectomy. The location of
each tumor was identified for each patient and categorized into one of the following
groups: right upper lobe (RUL), right middle lobe (RML), right lower lobe (RLL), left
upper lobe (LUL), or left lower lobe (LLL) lesions.
Overall survival (OS) was the primary study endpoint and was defined as the time
from diagnosis to the date of death from any cause. Lung cancer-specific survival
(LCSS), defined as the time of diagnosis to the date of death from lung cancer, was also
evaluated in our SEER database analysis. The NCDB, however, lacks data regarding lung
cancer specific death and therefore LCSS was not evaluated for this portion of the study.
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Pertaining to the NCDB only, four types of treatment facilities comprised of
community cancer programs (CCP), comprehensive community cancer programs
(Comprehensive CCP), teaching/research centers, or others were also included in all
analysis. Both CCP and Comprehensive CCPs have full range of services for cancer care;
however CCPs treat at least 300 cancer patients a year whereas Comprehensive CCPs
treat at least 650 cancer patients annually. Variables that were considered but could not
be included in the study due to limitations of available data in the NCDB included
performance status, specific details regarding staging procedures (i.e. CT/PET imaging,
lymph node staging procedure), medications, and comorbidities (a comorbid condition
scale in the form of Charlson/Deyo scores is available in the NCDB but only from 2003
onward and thus was not included in our multivariate analysis).

Statistical Analysis
T3>7cmN0 NSCLC, SEER Analysis
The overall survival (OS) and lung cancer-specific survival (LCSS) functions
stratified by type of surgery in the presence or absence of NRT were calculated using the
Kaplan-Meier method. Patients who were still alive at the end of the study were treated as
censored observations in the survival analysis. The log-rank test was used to evaluate
whether there were differences in the OS and LCSS among the treatment groups.
Comparisons on patient and tumor characteristics and provided therapy amongst different
age groups were performed using the Chi-squared test. The multivariable Cox regression
model was used to assess the effect of NRT followed by surgery as an independent
predictor of OS and LCSS. Hazard ratios (HR) and corresponding 95% confidence
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intervals were constructed in models adjusted for patient and tumor characteristics. Data
analysis was performed using SAS for Windows, version 9.2 (SAS Institute; Cary, NC).

T3>7cmN1 NSCLC, NCDB Analysis
Comparisons on patient and tumor characteristics and provided therapy amongst
different age groups were performed using the Chi-squared test. The OS functions
stratified by type of surgery in the presence or absence of neoadjuvant and adjuvant
therapy were calculated using the Kaplan-Meier method. Patients who were still alive at
the end of the study were treated as censored observations in the survival analysis. The
log-rank test was used to evaluate whether there were differences in the OS among the
treatment groups. The multivariable Cox regression model with backward elimination of
covariates with a P value >0.1 was used to assess whether various patient and tumor
characteristics (age, sex, race, histology, location of tumor, tumor size, facility type)
along with chosen therapy were significant independent predictors of OS. Hazard ratios
(HR) and corresponding 95% confidence intervals were constructed in models adjusted
for patient and tumor characteristics and therapeutic approaches. Data analysis was
performed using SAS for Windows, version 9.2 (SAS Institute; Cary, NC). Statistical
significance was defined as P <.05.
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RESULTS
T3>7 cmN0 NSCLC, SEER Analysis
Patient and tumor characteristics
The cohort was composed of 1,301 patients of whom 69 patients (5%) received
NRT followed by surgery as compared to 1,232 patients (95%) who had primary surgical
therapy (PST) (Table 1). The median follow-up time for the entire cohort was 25 months
(mean, 35 months; range, 0-131 months). The median age of the total population was 68
years (mean, 67 years; range, 31- 94 years). Forty-nine patients (71%) in the NRT group
were male and 800 patients (65%) who had PST were male. No male over 80 years of age
received NRT in comparison to 92 males (7%) above the age of 80 who received PST.
Most patients were Caucasian in both treatment groups (88% NRT; 86% PST). By the
end of the study period, 60% of the cohort (779 patients) had expired due to either lung
cancer-related mortality (568 patients; 44%) or other causes of death.
Adenocarcinoma was the predominant histology comprising 46% of the entire
cohort (593 patients) followed by squamous cell carcinoma which comprised 38% (500
patients) of the entire cohort. In the NRT group, squamous cell carcinoma (42%; 29
patients) was more prevalent than adenocarcinoma (29%; 20 patients). Tumor size did
not significantly vary among the different age populations (P=.16) in the entire cohort
and between the two treatment groups. Overall, patients with tumor sizes 8-8.9 cm had
the highest incidence of definitive treatment with either NRT followed by surgery (21
patients, 30%) or PST (391 patients, 32%) as compared to those with larger tumors.
Tumors 7.1-7.9 cm were the second most prevalent size group in the overall cohort (288
patients; 22%). Although distribution of tumor size was nearly equal among the different

16
age and treatment groups, tumor lobe location varied significantly (P<.0001). For the
entire cohort, right-sided tumors were more common than left-sided (56% vs. 44%) with
RUL and RLL lesions accounting for 52% of all tumors. Nearly 85% of patients treated
with NRT had upper lobe lesions (RUL, 46%; LUL, 38%).

Therapeutic approach
For the entire cohort, lobectomy was the most commonly employed surgical
approach with 85% of the population (1,110 patients) having undergone this type of
resection. The remaining 15% (191 patients) underwent pneumonectomy. The incidence
of lobectomies performed increased with advancing age while pneumonectomy incidence
decreased with increased age (P=<.0001). As noted earlier, PST was performed on the
majority of patients whereas only 5% (69 patients) received NRT followed by surgery.
Paralleling the overall cohort, patients in the NRT group underwent lobectomy (53
patients, 77%) more than pneumonectomy. Upon analysis of therapy provided in relation
to age, the incidence of NRT decreased with advanced age while the incidence of PST
increased to a peak of 35% for patients between the ages of 70-79 years (P<.0001). The
majority of patients treated with NRT were among the youngest age groups (20-69 years,
83%) whereas PST was performed mainly on a higher age population (60-79 years; 66%)
(Table 1).
The occurrence of NRT and PST was also analyzed in relation to tumor size.
Patients with smaller tumor sizes in the overall cohort had a higher incidence of being
treated with either NRT followed by surgery or PST than patients with increased tumor
size. Similarly, smaller tumors were more likely to have been treated with a lobectomy or
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pneumonectomy as compared to larger tumors, although the proportion of lobectomies
over pneumonectomies was greatest for tumors between 8-8.9 cm (Fig. 1).

Univariate survival analysis
The addition of NRT was not associated with improvements in the 5-year OS
(48% vs. 41%, P= .06) or LCSS (59% vs. 52%, P=0.12) compared to PST (Fig. 2). By
type of surgery performed, lobectomies were associated with significantly improved 5year OS (43% vs. 33%; P=.006) and LCSS (54% vs. 43%, P=.005) in comparison to
pneumonectomies for the entire cohort (Fig. 3). When patients were further divided by
type of surgery performed in the presence or absence of NRT, NRT did not significantly
improve the 5-year OS (NRT, 51% vs. PST, 43%; P=.08) or LCSS (NRT, 60% vs. PST,
54%; p=.19) in patients who had a lobectomy. Similarly, patients who had a
pneumonectomy did not benefit by the addition of NRT prior to surgery when
considering 5-year OS (NRT, 36% vs. PST, 32%; P=.33) and LCSS (NRT, 56% vs. PST,
42%; P=.24). Irrespective of survival time, however, the survival curves for PST, in
general, were consistently worse than for NRT followed by either a lobectomy or
pneumonectomy.

Multivariate analysis
After adjusting for patient and tumor characteristics, NRT was not associated with
significantly improved OS (P=.24) and LCSS (P=.21) for the entire cohort. Multivariate
regression analysis identified gender, age, tumor size, and type of surgery performed as
significant factors affecting OS, whereas only age, tumor size, and type of surgery were

18
found to significantly impact LCSS. Tumors ≥10 cm were associated with worse OS
(hazard ratio [HR] 1.39; P=.007) and LCSS (HR 1.54; P=.002) when compared to tumors
7.1-7.9 cm. Pneumonectomies were associated with significantly worse OS (HR, 1.32;
P=.007) and LCSS (HR, 1.38; P=.005) when compared to lobectomies (Table 2).
In a secondary analysis on the 69 patients who underwent NRT prior to surgery,
gender statistically affected survival with females having better OS (HR 0.27 [95%
confidence interval, 0.1-0.7], P=.007) and LCSS (HR 0.13 [0.03-0.51], P=.003) as
compared to males. Adenosquamous tumors had a significantly increased overall (HR
6.18 [1.26-30.2], P=.02) and lung-cancer specific (HR 11.69 [2.13-64.19], P=.005)
mortality risk than other histological types. The use of NRT prior to a lobectomy did not
produce a significant advantage in OS (P=.86) or LCSS (P=.7) in comparison to NRT
followed by a pneumonectomy (Table 3).

T3>7 cmN1 NSCLC, NCDB Analysis
Patient and tumor characteristics
The overall cohort was composed of 642 patients of whom 425 patients (66%)
underwent nonsurgical therapy (NST) and 217 patients (34%) underwent primary
surgical therapy (PST). The median age of the entire cohort was 68 years (range, 29-90
years) with a median follow up time of 11 months (range, 0-143 months). The majority of
patients were male (390 patients, 61%) and Caucasian (539 patients, 84%) and between
the ages 60-79 years (415 patients, 65%). By the end of the study period, 88% of the
cohort (565 patients) had expired. Patient characteristics are shown in Table 4.
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Therapeutic approach
Among the 425 NST patients, 43% (184 patients) were treated with CxR, 16%
RT, 15% Chemo, and 26% None. For the PST patients, 49% had S, 11% C-S, 14% CxRS, 16% S-C, 5% S-CxR, and 5% S-PORT. Lobectomy was the most commonly employed
surgical approach with 60% (131 patients) of the PST population having undergone this
type of resection (P=.002). The remaining 40% of the PST group underwent
pneumonectomy. For the entire cohort, definitive CxR was the most prevalent treatment
among all age groups except patients ≥80 years of age where 36% (28 patients) received
no treatment followed by 23% (18 patients) RT only. About half of the patients in the
overall cohort were treated in a comprehensive cancer center program (51%, 330
patients). A similar proportion was noted in the NST and PST groups separately.

Pathologic lymph node involvement
For PST patients, pathologic lymph node involvement (pN) was evaluated.
Among 56 patients who underwent neoadjuvant therapy prior to surgical resection (C-S,
CxR-S), 45% had an indeterminate pN reported (pNX), 27% had pN0, 25% had pN1 and
3% had pN2. Patients who underwent surgical resection in the absence or presence of
adjuvant therapy (S, S-C, S-CxR, S-PORT; n= 161) had 14% pN0, 72% pN1, 8% pN2,
and 6% pNX (P<.001).

Univariate survival analysis
Surgery was associated with significant improvements in 5-year OS (PST, 28%)
compared to 8% and 4% 5-year OS for NST and None, respectively (P<.001) (Fig. 4).
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Lobectomy was associated with a significantly better 5-year OS compared to
pneumonectomy among PST patients (L, 31%; P, 23%; P=.03). Smaller tumor sizes were
associated with improved OS compared to tumors ≥10 cm for the PST cohort (P= .006)
whereas tumor size variation did not affect OS for NST patients (P=.2).
The long-term survival of surgical and nonsurgical patients was further analyzed
by dividing patients by specific type of therapy provided. For NST patients there was a
significant stepwise improvement in 5-year OS with the addition of systemic therapy over
localized radiation therapy (None, 4%; RT, 2%; Chemo, 5%; CxR, 11%; P<.001).
Surgical patients who only received localized therapy had worse 5-year OS in
comparison to any multimodality treatment combination which included chemotherapy
(S, 16%; S-PORT, 18%; C-S, 40%; CxR-S, 44%; S-C, 38%; S-CxR, 40%; P<.001) (Fig.
5).

Multivariate analysis
After adjusting for patient and tumor characteristics, multivariate regression
analysis on the entire cohort identified age and type of surgery performed as significant
factors affecting OS (Table 5). Pneumonectomy was associated with a 49% increased
likelihood of death compared to lobectomy (hazard ratio [HR] 1.49 [95% confidence
interval, 1.08-2.05], P=.01). Type of therapy was also found to be an independent
predictor of OS. Using definitive CxR as a reference, chemotherapy had a nonsignificant
increase in HR whereas all other nonsurgical therapeutic approaches had a significantly
increased likelihood of death: Chemo HR 1.25 [0.93-1.68], P=.13; RT HR 1.5 [1.122.01], P=.007; None HR 2.87 [2.23-3.69]; P<.001. Local therapy in the form of surgery
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only was not associated with a significant difference in survival compared to definitive
CxR (S HR 0.8 [0.41-1.54], P=.5) whereas nearly all surgery with chemotherapy
combinations were associated with statistically improved OS in comparison to CxR only
(C-S HR 0.4 [0.18-0.88], P=.02; CxR-S HR 0.41 [0.19-0.9], P=.03; S-C HR 0.4 [0.190.85], P=.02) with the exception of S-CxR which demonstrated a trend towards survival
improvement (HR 0.5 [0.19-1.34], P=.17).
A separate multivariate analysis on the NST groups paralleled the results of the
overall cohort. Monotherapy was associated with an increased likelihood of death
compared to chemoradiation (Chemo HR 1.2 [0.92-1.66], P=.16; RT HR 1.5 [1.14-2.05],
P=.005). A comparison between the nonsurgical therapies demonstrated no significant
differences in HR between chemotherapy and RT but all three forms of NST were
associated with significantly improved survival compared to no treatment. In a separate
analysis of PST patients, tumors ≥10 cm were associated with worse OS (HR 1.89 [1.23]; P=.007) when compared to tumors 7.1-7.9 cm (Table 6). As seen on analysis of the
overall cohort, all multimodality therapies incorporating chemotherapy in a neoadjuvant
or adjuvant fashion among PST patients were associated with significantly reduced
likelihood of death compared to surgical resection only with the exception of S-CxR
which had a nonsignificant reduction in HR of 0.6 [0.26-1.35], P=.22. Finally,
pneumonectomies were associated with a significantly worse OS (HR 1.43 [1.02-1.99];
P=.04) when compared to lobectomies among the PST group.
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DISCUSSION
T3>7 cmN0 NSCLC, SEER Study
Surgery in the form of a lobectomy or pneumonectomy depending on the extent of
disease is still considered the gold standard, primary treatment for stage II NSCLC
disease. Adjuvant chemotherapy is sometimes recommended in certain high-risk cases in
order to reduce the risk of distance metastases which is the primary cause of death in
patients with NSCLC who die within 5 years of a complete surgical resection 8,33
However, the use of neoadjuvant therapy remains controversial for the management of
early stage NSCLC. This study is reflective of current practice patterns for this subset of
patients with Stage IIB NSCLC in that 95% of the cohort underwent surgery in the
absence of neoadjuvant therapy.
For early stage disease, complete surgical resection offers reasonably high rates of
cure. Definitive radiation therapy is only recommended for patients with early stage lung
cancer who are medically inoperable or refuse surgery due to potential adverse effects
from treatment-related toxicities and limited survival benefit33. In the SEER database,
neoadjuvant radiation therapy (NRT) was assumed to be a proxy for preoperative
chemoradiation due to the fact that preoperative radiation therapy alone has been
eschewed as the standard of care practice for at least two decades. Presumably, all
patients in this study had surgery of the primary tumor as part of a curative intent
paradigm. As stage II lung cancer has lower survival rates than stage I disease after
surgical resection, in part, due to higher distant recurrences the administration of
preoperative chemotherapy in addition to NRT would seem reasonable in order to
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minimize systemic dissemination. This same rationale has been the justification for
trimodality therapy among patients with more advanced stages of resectable lung cancer.
This study did not demonstrate a significant survival benefit associated with NRT
prior to surgery in patients with T3>7

cmN0

NSCLC tumors. The absence of a survival

difference mirrors the mixed survival results associated with neoadjuvant chemoradiation
followed by surgical resection for locally advanced NSCLC21,34-37. However, the 5-year
OS and LCSS rates achieved with NRT were non-significantly improved after trimodality
treatment in comparison to PST. Possible reasons for the absence of survival benefit in
our analysis might be inadequate power in the NRT group, the potential use of NRT on
larger tumors that underwent shrinkage prior to surgical resection, and variations in
radiation administered lending to the need to further investigate this finding on a larger
scale.
The role of neoadjuvant or induction therapy has long since been studied in patients
with resectable, early stage NSCLC. Neoadjuvant chemotherapy was shown to be
feasible and safe by the Bimodality Lung Oncology Team (BLOT) trial in 200338 and to
produce significantly lower risks in distant cancer recurrence in early stage NSCLC 23. In
two consecutive Intergroupe Francophone de Cancerologie Theracique or IFCT phase-III
trials, patients with stage IB or II NSCLC were given platinum-based neoadjuvant
chemotherapy followed by surgery and pathologic complete response (pCR), defined by
the absence of viable cancer cells in the resected surgical specimen, was evaluated.
Among the 492 patients analyzed, 41 (8.3%) achieved pCR and upon multivariate
analysis, pCR after preoperative chemotherapy was found to be a strong and favorable
prognostic factor of OS (Relative Risk [RR]= 0.34; 95% CI = 0.18–0.64) and disease-free
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survival (RR = 0.29; 95% CI = 0.16–0.56). Patients with Stage IB/II NSCLC in this study
who achieved pCR had a significantly improved 5-year OS of 80% compared with 55.5%
in the non-pCR group39.
Some clinicians have advocated the addition of preoperative radiation therapy to
systemic therapy in order to improve control of localized disease to lead to more of a
complete response than neoadjuvant chemotherapy alone. In a smaller study by Lococo et
al.,
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patients

with

T3/T4

node-negative

NSCLC

were

given

induction

chemoradiotherapy prior to surgery and survival patterns evaluated and compared to 40
T3/4N0 patients who directly underwent surgery. Reasonably safe and low toxicity rates
were recorded and complete pathologic response was obtained in 22% of the neoadjuvant
therapy group. Pathologic downstaging after neoadjuvant therapy, whether complete or
partial, was found to be the only independent factor associated with a better outcome
after surgery. Surprisingly, no significant differences were found when 5-year OS in the
neoadjuvant group (44%) and the surgery only group (37%) were compared40. These
results are similar to this study in that patients who received neoadjuvant therapy
exhibited a trend towards improved, though non-significant, survival rates compared to
patients who underwent surgical resection only (48% vs. 41%, respectively).
As with any form of surgical treatment, complete surgical resection is essential in
offering the best chance for cure. In Lococo et al.’s study, patients who underwent an
incomplete resection of their tumor had a rate of dying that was greater than 5 times when
compared to patients with negative surgical margins40. Our study evaluated long-term
survival of patients treated with surgery who obtained negative margins in order to
exclude patients that were likely to receive adjuvant therapy for treatment of residual

25
disease. Given the very large nature of T3>7

cmN0

NSCLC tumors, complete surgical

resection becomes increasingly challenging so the use of neoadjuvant therapy in order to
potentially reduce tumor burden or to allow for a more conservative surgery such as a
lobectomy is appealing. However, our results demonstrated no significant difference in
long-term survival compared to surgery alone.
Apart from achieving complete surgical resection, the type of surgery performed
may heavily affect survival patterns. No reports regarding randomized trials comparing
lobectomies to pneumonectomies for patients with NSCLC can be found in the literature
although several retrospective studies have shown improved 5-year OS rates of about 3748% with a lobectomy compared to 29-36% with a pneumonectomy41,42. With current
ACCP guidelines recommending a lobectomy over a pneumonectomy whenever
complete pathologic resection can be obtained8,33, our study demonstrates that this
recommendation is commonly applied in clinical practice as 85% of the entire cohort had
undergone this type of surgical resection. Moreover, lobectomies in our study were
associated with a similar and significantly improved 5-year OS estimate of 43%
compared to 33% with pneumonectomies.
Interestingly, two factors that have been shown to influence the effectiveness of a
surgery are how the surgery was performed and who performed it. Video-assisted
thoracoscopic surgery or VATS is a relatively recently developed surgical approach that
allows surgeons to view the inside of the chest cavity and remove the lung through small
incisions. Contrary to the traditional open thoracotomy which requires a longer incision
through one or more major muscles of the chest wall and the spreading of ribs to reach
the lung, a VATS lobectomy has been associated with shorter hospital stays, fewer
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complication rates and equivalent survival rates when compared to open lobectomy
especially when used to resect early stage NSCLC43-53. Furthermore, several studies have
shown lower complication rates and better long-term survival after anatomic pulmonary
resections performed by thoracic and cardiac surgeons instead of general surgeons54-57.
As the tumor sizes in our study were very large it is likely that many of the patients who
underwent a lobectomy had it performed via thoracotomy although information regarding
method of surgical procedure or surgeon subspecialty is unavailable in the SEER
database and thus was not accounted for in our analysis.
Tumor size has been recognized as a significant prognostic factor of survival
outcomes, particularly in patients with early stage NSCLC15,58,59. Similarly, Morgensztern
and colleagues recently demonstrated that tumor size is an independent predictor of
overall and lung-cancer specific survival in patients with locally advanced disease.
Patients with stage IIIA tumors >7 cm had a 14% increased risk of death from any cause
and an 18% increased risk of lung cancer death in comparison to stage IIIA tumors 5.1-7
cm in diameter. Moreover, the influence of tumor size on survival was reflected in the
improved OS and LCSS of patients with stage IIIB with small tumors than Stage IIIA
with larger tumors60. In our study, increasing tumor size was also associated with a higher
risk in both overall and lung-cancer specific mortality upon multivariate analysis of the
surgical subcohort. Tumors >10 cm in specific had significantly worse outcomes when
compared to any smaller tumor size category. This finding suggests a potential size cutoff
at 10 cm from which maximum therapeutic benefit on survival can be expected. The
decision for surgical resection of tumors >10 cm should be approached with caution as
we believe that the observed worse outcomes in these patients may be in part the result of
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a greater incidence of perioperative complications and postoperative residual disease. For
patients treated with neoadjuvant radiation therapy prior to surgery, tumor size was not a
significant predictor of OS (P=.18) and LCSS (P=.2).
This study has several limitations that are generally inherent in any retrospective
study of large databases. Information regarding the administration of chemotherapy,
either as neoadjuvant or adjuvant therapy, is unavailable in the SEER database therefore
we could not comment on the influence of neoadjuvant chemotherapy alone or
neoadjuvant chemotherapy when used concurrently with radiotherapy therapy on longterm survival of patients with T3>7 cmN0 NSCLC. It was also not possible to discern if
some of the patients underwent their neoadjuvant radiation therapy as part of a treatment
paradigm for a superior sulcus tumor. It is both possible and likely that some superior
sulcus tumors were included in this study, but presumably this number was reflective of
the proportion of superior sulcus tumors resected in the overall thoracic surgery
population which is less than 5%61,62. Arguably, the most significant limitation of this
study is the lack of knowledge regarding the use of adjuvant chemotherapy. In the study
period, the authors recognize that data emerged showing a benefit of adjuvant
chemotherapy for resected tumors >4 cm19. In the SEER database there is no ability to
discern which patients with tumors >7 cm received adjuvant chemotherapy and therefore,
the primary surgery cohort invariably included this subset of patients. Additionally, no
information regarding radiotherapy technique including total dose, fraction size, and
beam energy was available and was therefore not accounted for in our analysis.
Variations in chemotherapy and radiotherapy regimens are likely in our study population
and may have influenced the lack of significant NRT benefit on survival over anatomic
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pulmonary resection alone. However, this study did adjust for all available patient and
tumor characteristics.
In conclusion, the administration of neoadjuvant radiation therapy that most likely
represented chemoradiation therapy prior to surgery was not associated with
improvements in overall or lung-cancer specific survival as compared to primary surgical
therapy. Therefore, despite the large tumor size there is no significant associated benefit
from the use of neoadjuvant therapy for NSCLC tumors >7 cm with no lymph node
involvement. Respectable survival can be achieved after pulmonary anatomic resection in
this patient population. In terms of surgical approach, a lobectomy over pneumonectomy
appears to have a more favorable associated survival irrespective of tumor size, age,
gender, and histology. Tumors <10 cm in size, particularly tumors 7.1-7.9 cm, are
associated with the best long-term survival after surgery.

T3>7 cmN1 NSCLC, NCDB Study
After assessing survival outcomes associated with neoadjuvant therapy followed
by surgery for very large, node-negative NSCLC tumors, we sought to evaluate the effect
of neoadjuvant therapy and other various forms of multimodality therapy on long-term
survival of similarly sized tumors with positive lymph node involvement as studies are
lacking in this subpopulation of recently upstaged Stage IIIA disease. This study
demonstrates that patients who underwent multimodality therapy incorporating
chemotherapy in a neoadjuvant or adjuvant fashion had a significantly reduced likelihood
of death compared to those who underwent localized therapy or definitive
chemoradiation therapy.
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Improved survival of patients with locoregionally advanced NSCLC after
induction therapy has been demonstrated by several studies and is thought to reflect early
control of local and distant micrometastasis. In a randomized clinical trial involving 60
patients with Stage IIIA NSCLC, Rosell and colleagues observed that preoperative
chemotherapy with mitomycin, ifosfamide, and cisplatin followed by surgery resulted in
a significantly increased median survival of 26 months compared to 8 months in patients
treated with surgery alone63. In another trial performed at M.D. Anderson Cancer Center,
60 patients with clinical Stage IIIA NSCLC were randomly assigned between 1987 and
1993 to receive neoadjuvant chemotherapy with cyclophosphamide, etoposide, and
cisplatin followed by surgery or surgery alone. This trial demonstrated a median survival
and 3-year survival rate of 64 months and 60%, respectively, for patients who underwent
neoadjuvant chemotherapy compared to 11 months and 15%, respectively, for patients in
the surgery only treatment group64. Both of these trials show evidence of improved
survival rates with neoadjuvant chemotherapy. Several critiques exist for these trials in
that they were small, involved a heterogeneous set of Stage IIIA lesions, and included
adjuvant therapy in the form of radiotherapy or more systemic therapy. Furthermore,
other trials have failed to demonstrate any significant survival benefit with induction
chemotherapy for locally advanced NSCLC23. Neoadjuvant chemoradiation therapy
studies have also shown that it is both safe and feasible to administer to patients with
stage III NSCLC although there are mixed results in terms of its exact survival
benefit21,23,36,37,65-69 . Potential disadvantages to this trimodality therapy approach include
delayed control of the primary tumor with surgery and an increase in surgical morbidity
and mortality after induction therapy. However, the findings of this study clearly
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demonstrates an improvement in survival associated with neoadjuvant chemotherapy
with or without radiation therapy followed by surgery for patients with T3>7cmN1 NSCLC
lesions in comparison to surgery alone.
For patients treated with surgery followed by adjuvant chemotherapy in our study
there was a significantly improved 5-year OS estimate of 38% compared to 16-18% for
local surgical therapy (surgery alone or S-PORT). While a few trials and meta-analyses
have demonstrated that adjuvant cisplatin-based chemotherapy can significantly improve
long-term survival in select groups of Stage II and IIIA NSCLC patients 70, many other
trials have failed to show an advantage in disease-free survival or overall survival with
postoperative chemotherapy71-74. Problems such as inconsistent or mixed staging, lack of
effective chemotherapeutic agents prior to the 1990s, and incomplete administration of
planned doses have been prevalent issues within these studies. Interestingly, this study
shows that the timing of chemotherapy administration with respect to surgery does not
appear to affect survival. Neoadjuvant chemotherapy with or without radiotherapy
produced similar survival rates compared to adjuvant chemotherapy in the PST cohort
which were significant compared to surgery only and definitive chemoradiation.
Among the PST subcohorts that received systemic therapy, adjuvant
chemoradiation therapy was an exception in that it had an associated survival benefit that
was not significant (HR 0.5 [0.19-1.34], P=.17) compared to the others. Several
randomized controlled trials primarily involving patients with positive N2 nodal disease
such as the North American Intergroup trial E3590 have not shown any improvement in
disease-free and overall survival when radiation therapy is added to adjuvant
chemotherapy66,75,76. However, no sub-analysis on the effects of treatment on survival of
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patients with T3>7cmN1 NSCLC lesions if present has been performed. The small sample
size of patients who underwent adjuvant chemoradiation therapy may have influenced the
lack of significance for the 40% reduction in likelihood of death associated with S-CxR
over surgical resection only and warrants for further investigation of this finding on a
larger scale. Overall, these results suggest that the continuous debate of which form of
multimodality therapy is superior for managing locally advanced disease is irrelevant
when pertaining to T3>7cmN1 lesions.
Various patient and tumor characteristics can render a patient a poor surgical
candidate. Multiple comorbidities, poor pulmonary function, and significant spread of
disease are all factors that are known to lead to a worse prognosis, a realization that has
encouraged the discovery of the most optimal treatment strategy in medically inoperable
patients with locally advanced disease. Many earlier trials that evaluated the effectiveness
of sequential or concurrent chemotherapy with radiotherapy in comparison to
radiotherapy alone for unresectable Stage III NSCLC demonstrated improved though
non-significant survival times77-80. However, the average cohort size was small with
about 150 patients and there was much variability regarding chemotherapeutic agents
used and the administration of radiotherapy between these trials. Improvements in
platinum chemotherapy and radiotherapy techniques later on likely influenced the change
in observing a significant survival advantage associated with this bimodality
treatment81,82. In the Cancer and Leukemia Group B (GALGB) 8433 trial in particular,
patients with Stage III NSCLC who were treated with sequential chemotherapy followed
by radiation therapy were estimated to have a 2.8 fold higher 5-year OS estimate than
patients who received radiotherapy alone83. In our study, definitive chemoradiation
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therapy was the most prevalent nonsurgical treatment strategy with similarly significant
improvements in long-term survival in comparison to radiation therapy or chemotherapy
alone (5-year OS: 11%, 2%, 5%, respectively).
As discussed in our T3>7cmN0 NSCLC SEER analysis study, tumor size has been
recognized as a significant prognostic factor of survival outcomes, particularly for early
stage disease. In this study, tumor size was not found to be an independent predictor of
overall survival upon multivariate analysis of the entire cohort. However, tumor size
became a significant factor when analyzing the PST cohort only. Similar to T3>7cmN0
NSCLC tumors ≥10 cm that were surgically resected, patients in the PST cohort
exhibited significantly worse outcomes in survival with a hazard ratio of 1.9 (CI, 1.2-3)
when compared to tumors 7.1-7.9 cm. These results suggest a potential hazard associated
with surgical resection in the absence or presence of neoadjuvant or adjuvant therapy
when treating very large tumors. Therefore the decision for surgical resection of tumors
≥10 cm should be approached with caution as surgery appears to provide a significant
survival advantage only when part of a multimodality therapy involving systemic
therapy.
Although the NCDB contains a wealth of clinicopathologic and treatment data,
this study has several limitations in addition to the ones that are generally inherent to any
retrospective study of large databases. A major limitation was that knowledge of the
performance status of the patients in each group was not available. Therefore, patients
with better performance statuses may have been eligible and undergone more
interventional treatments (such as surgery with chemotherapy) associated with improved
survival which may have influenced the findings of this study. The majority of the
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patients in this study did not undergo surgery, and so while this scenario certainly is
plausible, it would seem unlikely that this explanation was the sole rationale for the
selection of the treatment modalities. Similarly, excluding the patients with positive
margins may have resulted in a group of surgery patients who would have been more
biased toward experiencing more favorable outcomes.
Information regarding chemotherapy, radiation therapy, or surgical therapy
administered is variable with many therapy descriptions being grouped into broad
categories defined by the NCDB. In the NCDB there is no ability to discern which
patients among those who received neoadjuvant chemotherapy prior to surgery (C-S,
CxR-S) also received adjuvant systemic therapy and therefore, these groups invariably
included this subset of patients. Pathologic “surprise” mediastinal lymph node
involvement (N2), although only comprising 11% of the PST cohort, may have
influenced the selected use of adjuvant chemotherapy or chemoradiation following
surgical resection in some of these patients who generally have poorer outcomes due to
greater lymph node spread of their disease. While this consideration has the potential to
lower the effects of adjuvant systemic therapy on survival, it reinforces the observed
significant survival advantage associated with adjuvant chemotherapy following surgical
resection. Similar to the broad definitions of therapy, information regarding specific
details of staging such as CT/PET scans and brain MRI imaging or type of lymph node
staging procedure is unavailable in the NCDB. Additionally, our primary endpoint was
overall survival as information on lung-cancer specific survival is lacking in the NCDB.
However, this study did adjust for all available patient and tumor characteristics. Lastly
and cumulatively, since the NCDB is a cancer registry it is difficult to isolate a possible
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pathophysiologic mechanism for the observed differences in survival. Indubitably, these
most likely are multifactorial in origin.
Lymph node downstaging has been associated with improved survival and has
been used to gauge the efficacy of chemoradiation therapy22,84,85. Determining whether
downstaging has occurred depends upon the knowledge of lymph node involvement prior
to the initiation of chemoradiation therapy coupled with pathologic information following
resection. For patients who received induction chemotherapy or chemoradiation in this
study, it is not possible to determine which patients were truly downstaged with systemic
therapy prior to surgical resection. Moreover, there is the possibility that a reduction in
tumor size and lymph node sterilization after neoadjuvant chemotherapy or
chemoradiation allowed for a more conservative resection such as a lobectomy over a
pneumonectomy in this group resulting in a selection bias. A more surprising finding
from the available pathologic lymph node data available is the fact that there is a
considerable percentage of patients that had no known pathologic lymph node status (Nx)
identified. It is unclear if this observation is secondary to either the true
underperformance of lymph nodes sampling at the time of resection or an artifact of data
collection.
This study is one of the largest known national database studies focused on
evaluating the effects of widely practiced treatment algorithms on long-term survival of
patients with T3>7cmN1 NSCLC. Although approximately two-thirds of the patients were
treated nonsurgically, pulmonary resections with chemotherapy, either with neoadjuvant
or adjuvant therapy, were associated with the best 5-year overall survival. Systemic
therapy in a multimodality setting appears to be crucial in maximizing long-term survival
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regardless of timing of administration to surgical resection. Finally, when surgical
resection is not feasible, definitive chemoradiation therapy should be considered as an
equal alternative to surgical resection alone when treating Stage IIIA-N1 NSCLC disease.
In general, very large tumors that are greater than 7 cm with no or minimal hilar
lymph node involvement present a unique set of problems for clinicians. Even though
complete resection of these tumors may appear daunting, both studies revealed that the
majority of surgical patients were able to achieve complete resection via a lobectomy
which is a more conservative surgical approach that was associated with significant
improvements in long-term survival compared to a pneumonectomy. However, caution
should be taken when dealing with tumors ≥10 cm in size regardless of lymph node
involvement. While trimodality therapy in the form of neoadjuvant or adjuvant therapy
with surgery was associated with the best survival outcomes in patients with very large
tumors with positive hilar lymph node involvement, the same does not appear to be true
for cases of node-negative disease. Neoadjuvant therapy followed by surgery for
treatment of T3>7

cmN0

NSCLC was associated with a modest trend toward improved

survival when compared to surgery alone although these results were shown to be nonsignificant. Taken into context of the overall staging system, T3>7 cmN0 NSCLC tumors
tend to behave like other subsets of early stage NSCLC lesions in that multimodality
therapy with surgery following neoadjuvant therapy does not appear to offer a greater
survival advantage. The spread of disease to local hilar lymph nodes in T3>7

cmN1

NSCLC makes the optimal treatment strategy less straight-forward. However, it appears
that several approaches to multimodality therapy are beneficial in this subset of patients
as long as systemic therapy is involved.

36
TABLES AND FIGURES
T3>7 cmN0 NSCLC, SEER Study
TABLE 1- Characteristics of Patients from the Overall Cohort and Each Age Group
Overall
20-59
60-69 yr
70-79 yr
80+ yrs
Characteristics
Cohort
yr
(n= 413)
(n= 441)
(n= 154)
(n= 1301)
(n=
293)
Therapy Sequence
PST

1232 (95)

261 (89)

388 (94)

430 (98)

153 (99)

NRT

69 (5)

32 (11)

25 (6)

11 (2)

1 (1)

849 (65)

180 (61)

279 (68)

298 (68)

92 (60)

49|800

20|160

19|260

10|288

0|92

1119 (86)

227 (77)

360 (87)

394 (89)

138 (89)

61|1058

27|200

23|337

13|384

1|137

115 (9)

45 (15)

36 (9)

26 (6)

8 (5)

4|111

2|43

1|35

1|25

0|8

67 (5)

21 (7)

17 (4)

21 (5)

8 (5)

4|63

3|18

1|16

0|21

0|1

500 (38)

83 (28)

166 (40)

191 (43)

60 (39)

29|471

13|70

11|155

5|186

0|60

593 (46)

140 (48)

172 (42)

204 (46)

77 (50)

20|573

8|132

7|165

4|200

1|76

88 (7)

25 (8)

34 (8)

19 (4)

10 (7)

6|82

4|21

2|32

0|19

0|10

34 (3)

8 (3)

11 (3)

13 (3)

2 (1)

2|32

0|8

1|10

1|12

0|2

86 (7)

37 (13)

30 (7)

14 (3)

5 (3)

12|74

7|30

4|26

1|13

0|5

Men, n (%)
NRT| PST

P Value

<.0001

.11

Race
White
NRT| PST
Black
NRT| PST
Other
NRT| PST

<.0001

Histology
SCC
NRT| PST
Adenocarcinoma
NRT PST
Large Cell
NRT| PST
Adenosquamous
NRT| PST
Other
NRT| PST

<.0001
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Laterality
Right
NRT| PST
Left
NRT| PST

735 (56)

180 (61)

220 (53)

247 (56)

88 (57)

37|698

18|162

12|208

6|241

1|87

566 (44)

113 (39)

193 (47)

194 (44)

66 (43)

32|534

14|99

13|180

5|189

0|66

341 (26)

107 (36)

105 (25)

92 (21)

37 (24)

32|309

17|90

11|94

4|88

0|37

58 (4)

19 (6)

19 (5)

13 (3)

7 (4)

0|58

0|19

0|19

0|13

0|7

336 (26)

54 (18)

96 (23)

142 (32)

44 (29)

5|331

1|53

1|95

2|140

1|43

276 (21)

61 (21)

112 (27)

80 (18)

23 (15)

26|250

12|49

10|102

4|76

0|23

290 (23)

52 (18)

81 (20)

114 (26)

43 (28)

6|284

2|50

3|78

1|113

0|43

288 (22)

68 (23)

85 (21)

99 (23)

36 (23)

17|271

9|59

7|78

1|98

0|36

412 (32)

87 (30)

129 (31)

143 (32)

53 (34)

21|391

7|80

9|120

5|138

0|53

213 (16)

51 (17)

68 (16)

74 (17)

20 (13)

9|204

4|47

3|65

2|72

0|20

195 (15)

36 (12)

78 (19)

66 (15)

15 (10)

16|179

8|28

5|73

3|63

0|15

193 (15)

51 (18)

53 (13)

59 (13)

30 (20)

6|187

4|47

1|52

0|59

1|29

.19

Lobe
RUL
NRT| PST
RML
NRT| PST
RLL
NRT| PST
LUL
NRT| PST
LLL
NRT| PST

<.0001

Tumor size, cm
7.1-7.9
NRT| PST
8-8.9
NRT| PST
9-9.9
NRT| PST
10-11.9
NRT| PST
≥12
NRT| PST
(Table continues…)

.16
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Type of Surgery
Lobectomy
NRT| PST
Pneumonectomy
NRT| PST

1110 (85)

230 (78)

346 (84)

388 (88)

146 (95)

53|1057

26|204

18|328

8|380

1|145

191 (15)

63 (22)

67 (16)

53 (12)

8 (5)

16|175

6|57

7|60

3|50

0|8

<.0001

Abbreviations: PST= primary surgical therapy; NRT= neoadjuvant radiation therapy. P Value based on x2
test.

TABLE 2- Multivariate analysis on overall and lung cancer-related mortality for overall cohort
Overall Mortality
RISK FACTOR

HR (95% CI)

Lung Cancer-Specific Mortality

P Value

HR (95% CI)

P value

Sex
Male
Female

Reference
0.82 (0.7-0.96)

Reference
.01

NA

.35

Age at diagnosis
20-59 yr

Reference

Reference

60-69 yr

1.47 (1.19-1.83)

.0005

1.36 (1.07-1.73)

.0127

70-79 yr

1.84 (1.49-2.26)

<.0001

1.57 (1.23-1.99)

.0002

80+ yr

2.33 (1.8-3.01)

<.0001

1.9 (1.41-2.57)

<.0001

Tumor size, cm
7.1-7.9

Reference

Reference

8-8.9

1.15 (0.94-1.41)

.17

1.16 (0.91-1.47)

.23

9-9.9

1.13 (0.89-1.43)

.33

1.13 (0.85-1.51)

.39

10-11.9

1.39 (1.09-1.76)

.007

1.54 (1.17-2.03)

.002

≥12

1.34 (1.05-1.7)

.019

1.49 (1.13-1.97)

.005

Type of Surgery
Lobectomy
Pneumonectomy

Reference
1.32 (1.08-1.6)

Reference
.007

1.38 (1.1-1.73)

.005
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TABLE 3- Multivariate analysis on overall and lung cancer-related mortality for NRT sub-cohort
Overall Mortality
RISK FACTOR

HR (95% CI)

Lung Cancer-Specific Mortality

P Value

HR (95% CI)

P value

Sex
Male

Reference

Female

0.27 (0.1-0.7)

Reference
.007

0.13 (0.03-0.51)

.003

Histology
SCC

Reference

Reference

Adenosquamous

6.18 (1.26-30.2)

.03

11.69 (2.13-64.19)

.005

Adenocarcinoma

0.45 (0.18-1.13)

.09

0.43 (0.14-1.31)

.14

Large Cell

1.13 (0.37-3.48)

.84

1.5 (0.46-4.88)

.5

Other

1.41 (0.53-3.73)

.49

1.61 (0.49-5.31)

.43

Age at diagnosis

.11

.91

Tumor size

.18

.2

Type of Surgery

.86

.7

400
350
Lobectomy
300
Frequency

Pneumonectomy
250
200
150
100
50
0
7

8

9

10

11 12 13 14 15 16
Tumor size group (cm)

17

18

19

Fig. 1. Frequency of type of surgery performed by tumor size. Tumor size group 7 cm begins at 7.1 cm.
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Fig. 2. A) OS and B) LCSS estimates for overall cohort stratified by type of therapy sequence.

Fig. 3. A) OS and B) LCSS estimates for overall cohort stratified by type of surgery performed.
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TABLE 4- Patient and tumor characteristics for the overall cohort by age group
Overall Cohort

20-59 yr

60-69 yr

70-79 yr

80+ yr

(n=642)

(n=150)

(n=209)

(n=206)

(n=77)

P value

Male, n (%)

390 (61)

92 (61)

133 (64)

128 (62)

37 (48)

.11

Female

252 (39)

58 (39)

76 (36)

78 (38)

40 (52)

Black

89 (14)

35 (23)

25 (12)

19 (9)

10 (13)

Other

14 (2)

***

***

***

***

White

539 (84)

112 (75)

178 (85)

183 (89)

66 (86)

Adenocarcinoma

139 (22)

39 (26)

41 (20)

46 (22)

13 (17)

Other

224 (35)

59 (39)

70 (33)

66 (32)

29 (38)

Squamous cell

279 (43)

52 (35)

98 (47)

94 (46)

35 (45)

LLL

101 (16)

17 (11)

36 (17)

36 (17)

12 (16)

LUL

183 (29)

46 (31)

58 (28)

58 (28)

21 (27)

RLL

110 (17)

16 (11)

37 (18)

44 (21)

13 (17)

RML

22 (3)

***

***

***

***

RUL

226 (35)

67 (45)

70 (33)

60 (29)

29 (38)

7.1-7.9 cm

136 (21)

37 (25)

38 (18)

47 (23)

14 (18)

8-8.9 cm

238 (37)

57 (38)

79 (38)

70 (34)

32 (42)

9-9.9 cm

121 (19)

25 (17)

45 (22)

39 (19)

12 (15)

≥10 cm

147 (23)

31 (20)

47 (22)

50 (24)

19 (25)

Characteristics
Gender

Race
.01

Histology
.26

Tumor Location
.21

Tumor Size

(Table continues…)

.78
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Surgical Approach
Lobectomy

131 (21)

48 (32)

37 (18)

39 (19)

***

Pneumonectomy

86 (13)

24 (16)

39 (19)

21 (10)

***

Nonsurgical

316 (49)

62 (41)

118 (56)

96 (47)

40 (52)

None

109 (17)

16 (11)

15 (7)

50 (24)

28 (36)

CxR

184 (29)

39 (26)

80 (38)

54 (26)

11 (14)

Chemo

65 (10)

15 (10)

22 (11)

17 (8)

11 (14)

RT

67 (10)

***

16 (8)

25 (12)

18 (23)

None

109 (17)

16 (11)

15 (7)

50 (24)

28 (36)

CxR-S

31 (5)

15 (10)

11 (5)

***

***

C-S

25 (4)

***

11 (5)

***

***

S

106 (17)

25 (17)

38 (18)

36 (17)

***

S-CxR

10 (2)

***

***

***

***

S-C

34 (5)

14 (9)

12 (6)

***

***

S-PORT

11 (2)

***

***

***

***

<.001

Therapy
<.001

Facility
CCP

120 (19)

20 (13)

48 (23)

35 (17)

17 (22)

Comprehensive CCP

330 (51)

71 (47)

103 (49)

118 (57)

38 (49)

Teaching or research

177 (8)

58 (39)

56 (27)

44 (21)

19 (25)

Other

15 (2)

***

***

***

***

.003

CCP, community cancer program; C-S, neoadjuvant chemotherapy + surgery; CxR-S, neoadjuvant
chemoradiation + surgery; CxR, chemoradiation; RT, radiation therapy; S, surgery; S-C, surgery +
adjuvant chemotherapy; S-CxR, surgery + adjuvant chemoradiation; S-PORT, surgery + postoperative
radiation therapy.
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TABLE 5- Multivariate analysis predicting overall survival among the overall cohort
Risk Factor

HR

95% CI L

95% CI U

P value

Age
20-59 yr

1.00

60-69 yr

1.18

0.93

1.5

.17

70-79 yr

2.1

1.65

2.67

<.001

80+ yr

2.01

1.48

2.74

<.001

1.08

2.05

.01

Type of Surgery
Lobectomy

1.00

Pneumonectomy

1.49

Therapy
CxR

1.00

Chemo

1.25

0.93

1.68

.13

RT

1.5

1.12

2.01

.007

None

2.87

2.23

3.69

<.001

CxR- S

0.41

0.19

0.9

.03

C-S

0.4

0.18

0.88

.02

S

0.8

0.41

1.54

.5

S-CxR

0.5

0.19

1.34

.17

S-C

0.4

0.19

0.85

.02

S-PORT

***

***

***

***

HR, Hazard ratio; 95% CI L, lower limit; 95 CI U, upper limit; CCP, community cancer program; C-S,
neoadjuvant chemotherapy + surgery; CxR-S, neoadjuvant chemoradiation + surgery; CxR,
chemoradiation; RT, radiation therapy; S, surgery; S-C, surgery + adjuvant chemotherapy; S-CxR, surgery
+ adjuvant chemoradiation; S-PORT, surgery + postoperative radiation therapy.
***, Value unavailable due to small sample size.
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TABLE 6- Multivariate analysis predicting overall survival among the PST cohort
Risk factor

HR

95% CI L

95% CI U

P value

Age
20-59 yr

1.00

60-69 yr

1.18

0.79

1.77

.42

70-79 yr

2.48

1.63

3.77

<.001

80+ yr

2.9

1.33

6.36

.008

Tumor Size
7.1-7.9 cm

1.00

8-8.9 cm

1.09

0.71

1.67

.68

9-9.9 cm

1.36

0.8

2.29

.25

≥10 cm

1.89

1.2

3

.007

1.02

1.99

.04

Type of Surgery
Lobectomy

1.00

Pneumonectomy

1.43

Therapy
S

1.00

CxR- S

0.5

0.3

0.85

.01

C-S

0.54

0.32

0.93

.02

S-C

0.49

0.31

0.78

.003

S-CxR

0.6

0.26

1.35

.22

S-PORT

1.29

0.66

2.53

.46

HR, Hazard ratio; 95% CI L, lower limit; 95 CI U, upper limit; CCP, community cancer program; C-S,
neoadjuvant chemotherapy + surgery; CxR-S, neoadjuvant chemoradiation + surgery; CxR,
chemoradiation; RT, radiation therapy; S, surgery; S-C, surgery + adjuvant chemotherapy; S-CxR, surgery
+ adjuvant chemoradiation; S-PORT, surgery + postoperative radiation therapy.
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Fig. 4. Overall survival estimates for overall cohort stratified by primary therapy. PST, primary surgical
therapy; NST, nonsurgical therapy.

Fig. 5. Overall survival estimates for A) NST and B) PST cohorts stratified by therapy. C-S, neoadjuvant
chemotherapy + surgery; CxR-S, neoadjuvant chemoradiation + surgery; CxR, chemoradiation; RT,
radiation therapy; S, surgery; S-C, surgery + adjuvant chemotherapy; S-CxR, surgery + adjuvant
chemoradiation; S-PORT, surgery + postoperative radiation therapy.
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